OraPharma, Inc. Begins Selling Arestin(TM) for the Adjunctive Treatment Of Periodontal Disease in Adults

Innovative New Treatment Uses Patented Technology to Deliver Sustained Release

Of Antibiotics Under the Gum Line for at Least Two Weeks



Apr 03, 2001, 01:00 ET from OraPharma, Inc.

    WARMINSTER, Pa., April 3 /PRNewswire/ -- OraPharma, Inc. (Nasdaq:   OPHM)
 announced today that on April 2, 2001, it began actively selling Arestin(TM)
 for the adjunctive treatment of adult periodontitis following scaling and root
 planing.
     "The launch of Arestin(TM) is another major milestone for OraPharma.  Our
 entire team has worked diligently to get us to this exciting point in our
 development" said Michael D. Kishbauch, President and Chief Executive Officer.
 "Arestin(TM) represents the first commercial product from our diverse pipeline
 and is now being sold to dental professionals by our own sales force in the
 United States.  This advanced technology will provide an important new weapon
 for the treatment of periodontal disease."
     Periodontal disease is a vastly under treated health problem that carries
 serious health risks.  It affects more than 50 million people in the United
 States; less than one-fifth of whom receive treatment.  Ultimately, this
 condition is the leading cause of tooth loss in the adult population.  In
 addition, studies suggest a possible systemic link between periodontal disease
 and overall health including conditions such as coronary heart disease,
 stroke, diabetes, and pre-term, low infant birth weight.
     Periodontal disease destroys supporting gum tissue and bone, forming
 "pockets" around the teeth in which plaque and bacteria accumulate.  The
 severity of periodontal disease is measured in part by the depth of these
 "pockets."
     Arestin(TM) uses patented microsphere technology to deliver the antibiotic
 minocycline beneath the gum, directly into the infected periodontal pocket
 after deep cleaning of the teeth and gums with a procedure known as scaling
 and root planing, a common method of treatment.  Arestin(TM) is highly
 bioadhesive, does not require retention dressings and will not leak or fall
 out.  In addition, Arestin(TM) does not require mixing or refrigeration in the
 dentist's office.
     Arestin(TM) is completely resorbed, which means patients don't have to
 return to the dentist for removal and can resume routine oral hygiene 12 hours
 after administration.  This is in contrast to other adjunctive antibiotic
 therapies that require the patient to significantly delay resumption of
 routine oral hygiene.
     OraPharma, Inc., a specialty pharmaceutical company, discovers, develops,
 and commercializes therapeutics for oral health.  The Company's other
 technological initiatives, which are in the preclinical stage of development,
 include a compound for the treatment of oral mucositis, a complication of
 cancer therapy, and an agent for bone and tissue regeneration.  During 2001,
 the Company will seek approval from the FDA to begin human clinical trials for
 both the oral mucositis and bone regeneration products.   In addition, the
 Company has two early stage product development projects, including a
 next-generation periodontal therapeutic, and a dental trauma preparation.
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the Private
 Securities Litigation Reform Act of 1995. These statements include statements
 regarding   the success of the Company's sales and marketing efforts for this
 product. In addition, these statements include statements regarding new
 product development initiatives for oral mucositis, bone and tissue
 regeneration, next generation periodontal therapeutics, and dental trauma
 preparations. The Company cautions readers that forward-looking statements are
 subject to certain risks and uncertainties, which could cause actual results
 to differ materially. Such risks and uncertainties include the possible
 failure of clinical trials for the Company's product candidates; the Company's
 ability to successfully market product candidates; the Company's ability to
 achieve milestones on which its licensed rights to commercialize Arestin(TM)
 are dependent; the prospect of continued losses by the Company; the Company's
 dependence on sole-source suppliers for the production of Arestin(TM); and
 other risks identified from time to time in the Company's reports filed with
 the U.S. Securities and Exchange Commission. We claim the protection of the
 Safe Harbor for forward-looking statements contained in the Private Securities
 Litigation Reform Act of 1995.
 
 

SOURCE OraPharma, Inc.
    WARMINSTER, Pa., April 3 /PRNewswire/ -- OraPharma, Inc. (Nasdaq:   OPHM)
 announced today that on April 2, 2001, it began actively selling Arestin(TM)
 for the adjunctive treatment of adult periodontitis following scaling and root
 planing.
     "The launch of Arestin(TM) is another major milestone for OraPharma.  Our
 entire team has worked diligently to get us to this exciting point in our
 development" said Michael D. Kishbauch, President and Chief Executive Officer.
 "Arestin(TM) represents the first commercial product from our diverse pipeline
 and is now being sold to dental professionals by our own sales force in the
 United States.  This advanced technology will provide an important new weapon
 for the treatment of periodontal disease."
     Periodontal disease is a vastly under treated health problem that carries
 serious health risks.  It affects more than 50 million people in the United
 States; less than one-fifth of whom receive treatment.  Ultimately, this
 condition is the leading cause of tooth loss in the adult population.  In
 addition, studies suggest a possible systemic link between periodontal disease
 and overall health including conditions such as coronary heart disease,
 stroke, diabetes, and pre-term, low infant birth weight.
     Periodontal disease destroys supporting gum tissue and bone, forming
 "pockets" around the teeth in which plaque and bacteria accumulate.  The
 severity of periodontal disease is measured in part by the depth of these
 "pockets."
     Arestin(TM) uses patented microsphere technology to deliver the antibiotic
 minocycline beneath the gum, directly into the infected periodontal pocket
 after deep cleaning of the teeth and gums with a procedure known as scaling
 and root planing, a common method of treatment.  Arestin(TM) is highly
 bioadhesive, does not require retention dressings and will not leak or fall
 out.  In addition, Arestin(TM) does not require mixing or refrigeration in the
 dentist's office.
     Arestin(TM) is completely resorbed, which means patients don't have to
 return to the dentist for removal and can resume routine oral hygiene 12 hours
 after administration.  This is in contrast to other adjunctive antibiotic
 therapies that require the patient to significantly delay resumption of
 routine oral hygiene.
     OraPharma, Inc., a specialty pharmaceutical company, discovers, develops,
 and commercializes therapeutics for oral health.  The Company's other
 technological initiatives, which are in the preclinical stage of development,
 include a compound for the treatment of oral mucositis, a complication of
 cancer therapy, and an agent for bone and tissue regeneration.  During 2001,
 the Company will seek approval from the FDA to begin human clinical trials for
 both the oral mucositis and bone regeneration products.   In addition, the
 Company has two early stage product development projects, including a
 next-generation periodontal therapeutic, and a dental trauma preparation.
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the Private
 Securities Litigation Reform Act of 1995. These statements include statements
 regarding   the success of the Company's sales and marketing efforts for this
 product. In addition, these statements include statements regarding new
 product development initiatives for oral mucositis, bone and tissue
 regeneration, next generation periodontal therapeutics, and dental trauma
 preparations. The Company cautions readers that forward-looking statements are
 subject to certain risks and uncertainties, which could cause actual results
 to differ materially. Such risks and uncertainties include the possible
 failure of clinical trials for the Company's product candidates; the Company's
 ability to successfully market product candidates; the Company's ability to
 achieve milestones on which its licensed rights to commercialize Arestin(TM)
 are dependent; the prospect of continued losses by the Company; the Company's
 dependence on sole-source suppliers for the production of Arestin(TM); and
 other risks identified from time to time in the Company's reports filed with
 the U.S. Securities and Exchange Commission. We claim the protection of the
 Safe Harbor for forward-looking statements contained in the Private Securities
 Litigation Reform Act of 1995.
 
 SOURCE  OraPharma, Inc.